Morbidity and mortality related to pancreatic surgery are still high: 30-40% and 3-10% respectively. As most complications are probably related to exocrine pancreatic secretion, its inhibition could improve the postoperative course. In 1979, Klempa saw a low complication rate after Whipple resection in a small number of patients treated with somatostatin, a powerful inhibitor of pancreatic exocrine secretion. The long acting somatostatin analogue, octreotide, also inhibits pancreatic exocrine secretion and can be given by subcutaneous injections. Two double blind, placebo controlled, multicentre studies with randomisation into parallel groups were recently performed to find out if peri and postoperative administration ofoctreotide (100 ,ug thrice daily subcutaneously) reduces the rate of complications specifically related to pancreatic surgery. Both trials consistently showed that octreotide can reduce substantially (over 40%) the risk of complications in these patients; the treatment acceptability was good.
Epidemiological data suggest that the worldwide incidence of pancreatic diseases is increasing. In Europe and the USA pancreatic carcinoma has reached a striking importance as a cause of death and as a source of health care related costs.' Therefore, pancreatic surgery is becoming more common. Surgery of the pancreatic gland is especially demanding, and entails complication and death rates of 30-40% and 3-21% respectively. The most important risk factor for complications is the pancreaticojejunal anastomosis performed after resection. (Table I) . Tables II and III report the frequency of patients with complications that were seen in the German and the Italian trial respectively. significantly lower in the group treated with octreotide than in the placebo group (p<0 005 and p=0-01 in the German and Italian trials respectively). If the patients are subdivided according to the risk stratum, there are also fewer complications in the octreotide treated arm; however, the difference is statistically significant only in the high risk group of the German study (p<0-001) and in the low risk Italian cases (p=0047), probably because the sample size becomes too small when the data are split up. The overall complication rates in patients given placebo were 55 4% and 29-2% in the German and the Italian trial respectively; this can be explained by the higher frequency of major resections performed in the first series. 
